Neuroendocrine Neoplasms clinical trials

Explore recruiting neuroendocrine neoplasms clinical trials.

Recruiting neuroendocrine neoplasms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Neoplasms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Neoplasms; Safety and Efficacy (RADNET)

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients with Cancer

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to test different doses of obrixtamig (BI 764532) combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

Belgium, France, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients with HepatoCellular Carcinoma, Biliary Tract Cancers or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Neuroendocrine Neoplasms trials by city

Neuroendocrine Neoplasms in Toronto Neuroendocrine Neoplasms in Vancouver Neuroendocrine Neoplasms in Montreal Neuroendocrine Neoplasms in Calgary Neuroendocrine Neoplasms in Edmonton Neuroendocrine Neoplasms in Ottawa Neuroendocrine Neoplasms in Winnipeg Neuroendocrine Neoplasms in Quebec City Neuroendocrine Neoplasms in Hamilton Neuroendocrine Neoplasms in Kitchener Neuroendocrine Neoplasms in London Neuroendocrine Neoplasms in Halifax Neuroendocrine Neoplasms in New York Neuroendocrine Neoplasms in Los Angeles Neuroendocrine Neoplasms in Chicago Neuroendocrine Neoplasms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease